Form 4: Abbott Laboratories Director John G. Stratton Reports Changes in Beneficial Ownership

Director John G. Stratton reports acquisition and disposal of Abbott Laboratories common shares and restricted stock units.

Summary

• On April 25, 2025, John G. Stratton, a director of Abbott Laboratories, reported changes in beneficial ownership.
• Stratton acquired 1,635 common shares without par value at a price of $0.
• Stratton disposed of 19,033 common shares.
• Following the reported transactions, Stratton beneficially owns 1,635 common shares.
• The reported transactions also involve restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program, which will be paid in Abbott common shares upon separation from service, death, or a change in control.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions by a company insider.

Future Outlook

The document does not contain any specific forward-looking statements regarding Abbott Laboratories' future performance.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It allows investors to monitor the actions of those with privileged information.

Stakeholder Impact

• The transactions reported may be of interest to shareholders as they provide insight into the actions of a company director.

Key Dates

Keywords

beneficial ownership, Form 4, Abbott Laboratories, director, Stratton, common shares, restricted stock units, insider trading